Overview of Colobolina D

Property	Description
Active Ingredient(s)	Hyoscine Butylbromide, Sodium Metamizole
Forms	Tablets, Solution for Injection
Pharmacological Class	Compound Antispasmodic and Non-opioid Analgesic
Primary Action	Simultaneous relief of muscle spasm and associated pain
Origin	Combination of Semisynthetic and Synthetic compounds

Colobolina D is a combination pharmaceutical preparation officially classified as a Compound Antispasmodic and Non-opioid Analgesic, leveraging a dual-action mechanism to manage acute discomfort. This fixed-dose drug is commonly presented as oral Tablets or as a sterile Solution for Injection, confirming its suitability for both Oral and Parenteral administration. The specific formulation is clinically recognized for its ability to target both the pain and the underlying spasm concurrently, providing a strategic approach to acute discomfort, such as intense abdominal cramping.

Composition and Pharmacological Classes

The core of Colobolina D consists of the two active ingredients: Hyoscine Butylbromide and Sodium Metamizole. Hyoscine Butylbromide is categorized as an Anticholinergic Spasmolytic, chemically defined as a quaternary ammonium compound and a Semisynthetic Derivative of the belladonna alkaloid hyoscine. This component primarily addresses the spasm, resulting in the relaxation of smooth muscles throughout the digestive and urinary tracts. The second component, Sodium Metamizole (also known as dipyrone), is a Pyrazolone Derivative classified as an Other Analgesic and Antipyretic. Sodium Metamizole is a potent Non-opioid Analgesic that is typically metabolized into active moieties.

Colobolina D's Dual Action Principle

The medicine’s general therapeutic purpose is rooted in its Dual Action Principle, providing simultaneous relief by combining the Smooth Muscle Relaxing Effect (Spasmolysis) with Central Pain Relief (Analgesia). This integrated action ensures the medicine addresses both the mechanical cause of acute tension and the body’s sensory response, defining the comprehensive therapeutic approach of this combination product.

What side effects are possible with Colobolina D?

Possible side effects and safety information

The safety profile of Colobolina D is a combination of the documented risks associated with its two components: an anticholinergic spasmolytic and a non-opioid analgesic. Adverse reactions are classified according to frequency and physiological system involvement, as detailed in official regulatory documentation.

Adverse Reaction Classifications

Classification	Examples of Documented Effects
Common	Tachycardia, Dry mouth, Constipation, Accommodation disorders (difficulty focusing visually).
Uncommon	Urticaria (hives), Pruritus, Dyshidrosis (abnormal sweating).
Rare	Agranulocytosis, Pancytopenia, Urinary retention.

Serious adverse reactions, though rare, are critical. The most significant concern associated with the analgesic component is Agranulocytosis, a potentially life-threatening decrease in white blood cells, and severe hypersensitivity events, including Anaphylactic Shock and Severe Cutaneous Adverse Reactions (SCARs).

Safety Considerations and Restrictions

Certain safety patterns are documented based on administration and patient populations. Hypotension (low blood pressure) and anaphylaxis are risks associated with or immediately following parenteral administration (injection), particularly if administered too rapidly.

Regulatory documentation also defines specific constraints for use in certain patient groups and conditions. The medicine is restricted in individuals with pre-existing conditions that involve mechanical obstruction, such as narrow-angle glaucoma, prostatic hypertrophy with urinary retention, and gastrointestinal or urinary tract mechanical stenosis. Caution is advised for patients with underlying cardiac conditions due to the potential for effects like tachycardia and hypotension.

Overdose and Emergency Response

Overdose of Colobolina D presents with a dual toxicity profile, involving both active components. Documented manifestations include the anticholinergic toxidrome, characterized by symptoms such as dry mouth, urinary retention, flushing, and tachycardia. Concurrently, central nervous and cardiovascular effects, such as confusion, somnolence, and severe hypotension, are documented, which may progress to circulatory shock, convulsions, and coma.

Immediate Medical Attention is required for any suspected overdose or accidental ingestion. Urgent medical assistance must be sought for specific manifestations, including the onset of fever, sore throat, or painful mucosal changes suggestive of blood dyscrasia (agranulocytosis), or the development of a painful, red eye with loss of vision.

Management, as described in regulatory documents, is symptomatic and supportive. Procedures include gastric lavage and the administration of activated charcoal for oral exposure. Continuous monitoring of blood pressure, heart rate, and respiration is mandated. Anticholinergic symptoms are known to respond to parasympathomimetics. The risk of serious cardiac adverse reactions is noted as increased in patients with underlying cardiac disease or unstable circulation.

Therapeutic Uses of Colobolina D

What Colobolina D Treats: Main Uses and Benefits

Colobolina D provides symptomatic support by managing clusters of symptoms related to heightened physiological activity and physical discomfort. As an analgesic and antispasmodic combination, it is applied across domains where short-term symptom management is appropriate and is relevant for managing symptoms that interfere with daily comfort. This drug class is utilized for conditions presenting with systemic or localized discomfort.

Key Areas of Symptom Relief

This medication is commonly used to help with intense pain, cramping, and fever. It addresses symptom clusters that may become disruptive, such as painful spasms in the digestive or urinary tracts, and general pronounced pain combined with elevated body temperature.

“This type of medication may assist with maintaining functional stability during symptomatic phases, supporting patients through difficult episodes.”

By easing the discomfort and strain associated with these acute manifestations, Colobolina D may contribute to improved day-to-day comfort during periods of heightened symptoms. It is often used in settings where short-term symptomatic assistance is needed for intensified symptoms.

Quick Fact: Relief for Spasms and Pronounced Pain

Regulatory References

ATC/DDD Index on Antispasmodics in combination with Analgesics

Eligibility and Restrictions for Use

Official Eligibility for Colobolina D Use

Regulatory authorities define strict population eligibility criteria for this combination medicine, classifying individuals as approved users, those who require caution, or those who are absolutely prohibited (contraindicated). The standard approved population is adults and adolescents aged 15 years and older.

Absolute Contraindications

Use of Colobolina D is strictly forbidden by official labeling in patients with:

Hypersensitivity to Metamizole, Hyoscine Butylbromide, or related pyrazolone compounds.
A history of Agranulocytosis or pre-existing severe impaired bone marrow function.
Conditions susceptible to anticholinergic effects, such as Myasthenia Gravis, mechanical stenosis of the gastrointestinal or urinary tracts, or untreated narrow-angle glaucoma.
Acute Intermittent Hepatic Porphyria.
Third trimester of pregnancy.

Age and Condition Restrictions

Population Group	Regulatory Status
Infants (< 3 months or < 5 kg)	Contraindicated (for specific formulations).
Children (< 15 years)	Not recommended for fixed-dose oral forms.
Impaired Liver/Kidney Function	Use with caution is required.
Pregnancy/Lactation	Contraindicated in the third trimester and not recommended while breastfeeding.
Older Adults	Use requires caution due to a higher risk of organ impairment.

These official statements define who is eligible, ensuring the medicine is only used within regulatory safety boundaries.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Colobolina D, based on regulatory prescribing information for its active components, Hyoscine Butylbromide and Sodium Metamizole.

Official Interaction Statements

Pharmacokinetic Interactions: The Sodium Metamizole component is formally described as an inducer of Cytochrome P450 enzymes CYP3A4, CYP2B6, and CYP2C19, and an inhibitor of CYP1A2. This documented enzyme activity can lead to reduced exposure for co-administered medicines metabolized by these pathways, such as substrates of CYP3A4 and CYP2C19. Conversely, Hepatic Microsomal Enzyme Inducers (e.g., Barbiturates, Phenylbutazone) are noted to reduce the duration and half-life of Sodium Metamizole.
Pharmacodynamic Interactions: The anticholinergic effects of Hyoscine Butylbromide may be intensified when co-administered with other anticholinergic substances, including tri- and tetracyclic antidepressants, certain antihistamines, and some antipsychotics. Additionally, the tachycardic effects of beta-adrenergic agents may be enhanced. The drug is also noted to inhibit the anti-platelet effect of acetylsalicylic acid (aspirin) when both are taken simultaneously.
Mandatory Restrictions: The co-administration of Hyoscine Butylbromide Injection with anticoagulant drugs is explicitly contraindicated if the injection is administered via the intramuscular route.

Mechanism of Action

Blocking Excitatory Nerve Signals

This mechanism focuses on Hyoscine Butylbromide, which acts as a competitive antagonist primarily at muscarinic acetylcholine receptors in the visceral organs. By inhibiting the action of the body's natural neurotransmitter acetylcholine, the drug decreases cholinergic signaling to the smooth muscle, resulting in a reduction of muscle tone in the visceral tracts.

Central Anti-Nociception and Signal Modulation

This mechanism is driven by Sodium Metamizole, which acts through multiple pathways to establish anti-nociceptive effects. Its active metabolites target enzymes like Cyclooxygenase-3 (COX-3) in the CNS to reduce the synthesis of pain-mediating prostaglandins and modulate the activity of the body’s opioidergic and cannabinoid systems. This engagement of descending pain inhibitory pathways contributes to central anti-nociception.

Dual-Mechanism Smooth Muscle Relaxation

The final effect relies on a synergistic action: Hyoscine Butylbromide provides neurogenic spasmolysis by blocking nerve signals, while Sodium Metamizole provides myotropic spasmolysis by directly modulating intracellular calcium dynamics within the muscle cells. This combined mechanistic action establishes comprehensive physiological modulation of muscle tone.

Dosage and Administration Information

Colobolina D is administered via two primary methods: the Oral route using tablets, or the Parenteral route using a solution for Intravenous (IV) and Intramuscular (IM) injection. The medicine is intended for short-term, acute use and is not designated for continuous daily administration without investigation into the underlying condition.

For the injectable formulation, the standard adult unit dose is one ampoule, containing 20 mg of Hyoscine Butylbromide and 2.5 g of Metamizole sodium monohydrate. This unit dose may be repeated up to three times daily, provided an interval of several hours is maintained between administrations. The administration of the injection is subject to procedural constraints: the intravenous injection must be performed slowly, and administration by any parenteral route must occur under medical supervision with patient monitoring. The solution must not be administered subcutaneously.

The oral formulation is typically dosed at one to two tablets per administration, with a maximum daily frequency of three times. Regarding population-specific instructions, a dose reduction may be necessary for older adults and individuals who have impaired renal or hepatic function, which is a key consideration for proper dosing. This entire use protocol is structured around clinical administrative practice.

Recent Clinical Evidence

Colobolina D: Recent Clinical Evidence

Evidence for use in Acute Pain and Spasm (e.g., Colic)

Research on Colobolina D, combining an antispasmodic and an analgesic, has been applied in studies examining patient-reported experiences of intense, sudden physical discomfort like colic. These short-term Randomized Controlled Trials (RCTs) and systematic reviews evaluated the combination in studies exploring short-term changes in intense, acute pain associated with muscle spasms. Outcomes related to physical discomfort monitored included pain intensity changes and the time elapsed until patients reported a measurable change in pain. Research highlights changes measured during the study period but research does not determine whether an individual will respond similarly.

Evidence for use in Symptomatic Gastrointestinal Cramping

Research relevant in trials assessing short-term or episodic symptom patterns has focused on its use in conditions involving periods of heightened symptoms, such as general abdominal discomfort and cramping. Studies explored how the medicine's components was evaluated in individuals experiencing this acute, non-colicky pain. Findings describe patterns observed in the studies where patients reported various degrees of measured change in cramping and pain scores. Some research describes patterns where the antispasmodic component was associated with measured changes in gut smooth muscle activity.

Research on Long-Term Outcomes and Follow-up Duration

The primary focus of studies has been on episodes where symptoms become more noticeable. Because the medicine was studied for acute symptoms, the follow-up durations were limited in the key studies. Long-term effects are not fully established and there is limited information for long-term outcomes such as patterns of recurrence after the initial acute phase has passed. The current research provides context but not individual predictions about long-term use.

Evidence in Specific Patient Populations

The existing research was studied for populations characterized by fluctuating or episodic manifestations, but sample sizes were modest for specific groups. The results apply only to the populations studied, which were predominantly Adults. Data for certain groups remain insufficient, including for older adults and children and adolescents. Research in patients with certain comorbid conditions that affect the digestive or urinary tracts also remains insufficient.

Current Evidence Gaps and Areas of Uncertainty

A primary research limitation frame is that comparative evidence is lacking for the fixed combination against placebo in many modern trial designs. Much of the evidence was studied for the individual active components separately. The findings were mixed regarding the comparative patterns of the combination against other agents. Overall, the available studies help show what has been observed so far, but certainty remains low for long-term use.

Key Studies & References

Health Canada Drug Product Database Monograph: Fixed-Dose Combination Antispasmodic and Analgesic Product

Frequently Asked Questions (FAQ)

Common questions about Colobolina D (FAQ)

Q: What is the main difference between Colobolina D and other medicines for the same condition?

Official classification describes Colobolina D as a Compound Antispasmodic and Non-opioid Analgesic, representing its dual action. According to regulatory sources, it is designed to provide simultaneous relief by relaxing smooth muscle spasm and addressing associated pain. Official research summaries indicate that comparative evidence against all other agents may be limited.

Q: How quickly does Colobolina D usually start to work?

Official information indicates that Colobolina D has a relatively rapid onset of action, especially when administered via injection. For the combination product, studies have reported that relief from symptoms was noted to start within one hour of administration.

Q: How long can a person stay on Colobolina D treatment?

Regulatory protocols state that this medicine is intended for short-term, acute use and is not meant for continuous daily use without a medical reassessment. Regulatory documents indicate that the risk of certain serious side effects, such as agranulocytosis, may be related to treatment durations exceeding a few days.

Q: Is Colobolina D addictive or habit-forming?

The analgesic component is classified as a Non-opioid Analgesic (a Pyrazolone derivative). Pharmacological texts generally describe this class of medicine as having a low potential for dependence or habit formation.

Q: How long after taking Colobolina D can I drink alcohol?

Official safety warnings indicate that combining the medicine with alcohol may intensify central nervous system effects, such as drowsiness or fatigue. Regulatory guidance describes that caution should be exercised regarding alcohol use during treatment.

Q: Is this medication considered a first-line treatment?

Colobolina D is authorized for use in treating moderate to severe pain and fever that is associated with muscle spasm, particularly where other analgesic options are not considered suitable. The authorized indication defines the circumstances under which the medicine is used.

Q: Does Colobolina D affect mood or anxiety levels?

The analgesic component is known to modulate certain pathways in the central nervous system. Official documentation lists some potential neurological effects, such as dizziness and somnolence (drowsiness). Changes to mood or anxiety levels are not documented as common side effects.

Q: Is Colobolina D used for any conditions other than the main approved use?

Regulatory documents focus on the approved use for the simultaneous relief of muscle spasm and associated pain. The medicine is not formally approved for conditions outside of this defined scope.

Q: Where can I find the official document (like the prescribing information) for Colobolina D?

The official product documentation, often called the Prescribing Information or Summary of Product Characteristics, is provided by the regulatory agency in your country. You can usually locate this official document on the websites of bodies like the FDA, EMA, or your national health authority.

Q: Is it okay to take Colobolina D at different times each day?

The official dosing protocol focuses on ensuring a necessary interval of several hours is maintained between administrations to avoid exceeding the maximum daily dose. Regulatory documents prioritize adherence to the minimum time interval over consistency in the specific time of day.

Q: Are there different versions or brands of Colobolina D?

Colobolina D is the name given to this specific fixed-dose combination of Hyoscine Butylbromide and Sodium Metamizole. While the composition is officially defined, other brands containing this exact combination may be marketed depending on the country, and individual components may be available as generics.

Q: Is it true that Colobolina D can affect my sleep?

Official documentation lists side effects that may potentially impact sleep patterns. These include somnolence (drowsiness) from the analgesic component and tachycardia (fast heart rate) from the antispasmodic component. Both effects could potentially interfere with normal sleep patterns.

Q: Does Colobolina D interact with herbal supplements?

Official patient information often states that there is insufficient information or evidence available to confirm the safety of combining this medicine with herbal remedies or supplements. Due to this lack of data, consulting a healthcare professional is generally advised for guidance.

Q: Does Colobolina D affect my ability to drive or operate machinery?

Official safety warnings indicate that side effects such as accommodation disorders (difficulty focusing), dizziness, or somnolence may occur. Individuals should consider avoiding driving or operating machinery if these specific effects are experienced.

Q: How reliable is the research evidence for Colobolina D's effectiveness?

Official research summaries note that the studies conducted focused on acute symptoms and had limited follow-up duration. Because of this, official assessments acknowledge that the certainty remains low for long-term outcomes. Comparative evidence against other treatments is also noted to be mixed or lacking in some areas.

Q: What should I do if the side effects of Colobolina D bother me?

If you experience any concerning or bothersome side effects, especially signs of serious complications (like fever or yellowing of the skin), regulatory guidance for managing serious adverse reactions includes stopping the medicine and seeking immediate professional consultation.

Q: Is it normal to feel a mild headache when starting Colobolina D?

Official documentation lists adverse effects by frequency. In reviews for the analgesic component, headache has been reported, although it is not consistently classified as a common effect. Official documentation classifies effects by frequency.

How should Colobolina D be stored and disposed of?

The storage and disposal of Colobolina D must be handled according to official regulatory specifications to maintain product stability and ensure public safety.

Storage Requirements

Labeled Storage Entity	Official Requirement
Temperature Requirements	Store below 30 C (86 F).
Protection Requirements	Must be protected from light and kept in the original package.
Child Protection	Must be kept out of the sight and reach of children.
Post-Opening Stability	The solution for injection, if applicable, must be used immediately after opening or dilution.

Disposal Instructions

All disposal procedures for unused or expired product must be done in accordance with local requirements. The medicine must not be disposed of via wastewater or household waste. Consult a pharmacist for proper disposal methods to ensure compliance with environmental protection regulations.

Colobolina D